By

Luke Timmerman

23
Mar
2020

New Drugs at Low Prices: Alexis Borisy and Melanie Nallicheri of EQRx on The Long Run

Today’s guests on The Long Run are Alexis Borisy and Melanie Nallicheri. Alexis is the chairman and CEO of EQRx, and Melanie is the president and chief operating officer. EQRx is a startup in Cambridge, Massachusetts. It aspires to develop new medicines for serious diseases like cancer. That’s nothing unusual. What is unusual is that EQRx is seeking to create...
Read More
17
Mar
2020

Dangerous Shortages of Equipment: A Nurse’s View from the Front Lines of Pandemic

[Editor’s Note: this is a statement from a nurse in New York City who I spoke with earlier today. Her concerns about dangerous shortages of Personal Protective Equipment for healthcare workers were echoed in an article today by Seattle physicians in the Journal of the National Comprehensive Cancer Network. The nurse wishes to remain anonymous.] I am a registered nurse...
Read More
12
Mar
2020

COVID-19: Collective Problem-Solving Time

The alarm bells have been ringing for weeks. Stunningly, millions of people in the US weren’t listening, or didn’t want to listen. We have wasted precious time in defending ourselves against the coronavirus pandemic. The horrible news from Italy is slowly starting to sink in for us in the US, and other parts of the world. Sports cancellations, a prime-time...
Read More
9
Mar
2020

Living Life Fully with Stage 4 Lung Cancer: Isabella de le Houssaye on The Long Run

Today’s guest on The Long Run is Isabella de la Houssaye. Isabella is a former attorney on Wall Street, a mother of five kids, and a terrific endurance athlete. She’s run marathons around the country, ultramarathons, and even completed an Ironman triathlon. She’s also a Stage 4 lung cancer patient. She owes her life, and her vitality, to some extraordinary...
Read More
27
Feb
2020

Gilead, Moderna Rise to the Occasion, Esperion Goes Back-to-Back, & Sangamo’s Big Neurology Deal

This week’s Frontpoints is a compilation of two weeks of deals, financings, and personnel moves. To synthesize the main events of this eventful stretch, subscribers to Timmerman Report may read on. Coronavirus Thoughts If we learn one big lesson from this public health crisis, it should be that we need to continue to invest in our public agencies dedicated to...
Read More
11
Feb
2020

The Cell Therapy Puzzle: Jane Grogan on The Long Run

Today’s guest on The Long Run is Jane Grogan. Jane is the chief scientific officer of South San Francisco-based Arsenal Bio. Like the name suggests, Arsenal is pulling together a stockpile of potent tools of modern biology. As the company describes itself: Arsenal will integrate technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and...
Read More
27
Jan
2020

Scientists at the Movies: Relay Therapeutics CEO Sanjiv Patel on The Long Run

Today’s guest on The Long Run is Sanjiv Patel. Sanjiv is the CEO of Cambridge, Mass.-based Relay Therapeutics. Relay is among a new crop of drug discovery companies driven by advances in computational chemistry. What does that mean? As I wrote in Timmerman Report a little over a year ago: “The basic concept is all about starting with high-quality crystallography...
Read More
23
Jan
2020

Much Ado about Coronavirus and 23andMe Hits the Wall

This was a quiet week in biopharma. Review it in your weekly Frontpoints. This Week in Alarmism Every year, we hear about an infectious disease scare that generates massive coverage, way out of proportion with the actual threat posed. Remember Mad Cow disease, SARS, Bird flu, Ebola, etc. etc? I’ve been in newsrooms providing saturation coverage of such things, and...
Read More
12
Jan
2020

EQRx Taps Zeitgeist, Raises $200m For Innovative Drugs at Aggressive Low Prices

Alexis Borisy is smart. As in high IQ. But there’s more to biopharma than that. “As my grandmother used to say, ‘You can be smart, smart, smart…but dumb,’” Borisy said. Some old wisdom is part of what’s driving Cambridge, Mass.-based EQRx. The company, started by the former Third Rock Ventures partner and backed by $200 million of “smart money” in...
Read More